Business structure centered on prescription pharmaceuticals
First written in FY2016. 24 of 27 entries say "Restated". Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024RestatedAnnual report
「The positioning of the Company and its affiliates within the Group (the Company and its affiliates), and their relationship with the segments, are as follows.」
The Group has reaffirmed its structure of operating 4 businesses centered on pharmaceuticals: merchandise sales, information services and construction contracting. - FY2024-Q2RestatedAnnual report
「During the second quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
Reconfirms that there were no material changes to the business operations or major affiliates. - FY2023-Q3RestatedAnnual report
「During the third quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
Reconfirms that there were no material changes to the business operations or major affiliates. - FY2023-Q2RestatedAnnual report
「During the second quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
Reconfirms that there were no material changes to the business operations or major affiliates. - FY2023-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
Reconfirms that there were no material changes to the business operations or major affiliates. - FY2022RestatedAnnual report
「The Group (the Company and its affiliates) comprises 6 companies: the Company, 3 consolidated domestic subsidiaries, 1 unconsolidated domestic subsidiary and 1 unconsolidated overseas subsidiary. Its principal business is the manufacture and sale of prescription pharmaceuticals, along with the purchase and sale of related materials, systems development and information processing, construction contracting, facility and equipment management, information gathering and development support, and other services.」
The 6-company structure and business model centered on prescription pharmaceuticals have been reaffirmed. - FY2022-Q3RestatedAnnual report
「During the third quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
Reconfirms that there were no material changes to the business operations or major affiliates. - FY2022-Q2RestatedAnnual report
「During the second quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
Reconfirms that there were no material changes to the business operations or major affiliates. - FY2021-Q2RestatedAnnual report
「During the second quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
Reconfirms that there were no material changes to the business operations or major affiliates. - FY2021-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
Reconfirms that there were no material changes to the business operations or major affiliates. - FY2020ReframedAnnual report
「The Group (the Company and its affiliates) comprises 6 companies: the Company, 3 consolidated domestic subsidiaries, 1 unconsolidated domestic subsidiary and 1 unconsolidated overseas subsidiary. Its principal business is the manufacture and sale of prescription pharmaceuticals, along with the purchase and sale of related materials, systems development and information processing, construction contracting, facility and equipment management, information gathering and development support, and other services.」
The Group structure increased from the previous 5 companies to 6, with 1 unconsolidated domestic subsidiary added. The business structure centered on prescription pharmaceuticals has been maintained. - FY2020-Q3RestatedAnnual report
「During the third quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
The absence of material changes in the nature of the businesses and major affiliates has been reaffirmed. Changes to the reportable segment classification will be tracked in a separate thread. - FY2020-Q2RestatedAnnual report
「During the second quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
The absence of material changes in the nature of the businesses and major affiliates has been reaffirmed. However, the classification of reportable segments has changed. - FY2020-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
Reconfirms that there were no material changes to the business operations or major affiliates. - FY2019RestatedAnnual report
「The Group comprises 5 companies: the company submitting consolidated financial statements (hereinafter, the “Company”), 3 consolidated domestic subsidiaries and 1 unconsolidated overseas subsidiary. Its principal business is the manufacture and sale of prescription pharmaceuticals, along with the purchase and sale of related materials, systems development and information processing, construction contracting, facility and equipment management, information gathering and development support, and other services.」
The 5-company structure and business model centered on prescription pharmaceuticals have been reaffirmed. - FY2019-Q3RestatedAnnual report
「During the third quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
Reconfirms that there were no material changes to the business operations or major affiliates. - FY2019-Q2RestatedAnnual report
「During the second quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
Reconfirms that there were no material changes to the business operations or major affiliates. - FY2019-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
Reconfirms that there were no material changes to the business operations or major affiliates. - FY2018RestatedAnnual report
「The Group comprises 5 companies: the company submitting consolidated financial statements (hereinafter, the “Company”), 3 consolidated domestic subsidiaries and 1 unconsolidated overseas subsidiary. Its principal business is the manufacture and sale of prescription pharmaceuticals, along with the purchase and sale of related materials, systems development and information processing, construction contracting, facility and equipment management, information gathering and development support, and other services.」
The 5-company structure centered on prescription pharmaceuticals, combined with information services, merchandise sales and construction contracting, has continued. - FY2018-Q3RestatedAnnual report
「During the third quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
Reconfirms that there were no material changes to the business operations or major affiliates. - FY2018-Q2RestatedAnnual report
「During the second quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
Reconfirms that there were no material changes to the business operations or major affiliates. - FY2018-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
Reconfirms that there were no material changes to the business operations or major affiliates. - FY2017ReframedAnnual report
「The Group comprises 5 companies: the company submitting consolidated financial statements (hereinafter, the “Company”), 3 consolidated domestic subsidiaries and 1 unconsolidated overseas subsidiary. Its principal business is the manufacture and sale of prescription pharmaceuticals, along with the purchase and sale of related materials, systems development and information processing, construction contracting, facility and equipment management, information gathering and development support, and other services.」
The Group structure was streamlined from the 7 companies reported in the previous fiscal year to 5, and the transfer of an unconsolidated subsidiary was also reported. The business structure centered on prescription pharmaceuticals has been maintained. - FY2017-Q3RestatedAnnual report
「During the third quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
Reconfirms that there were no material changes to the business operations or major affiliates. - FY2017-Q2RestatedAnnual report
「During the second quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
Reconfirms that there were no material changes to the business operations or major affiliates. - FY2017-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no material changes in the nature of the businesses operated by the Group (the Company and its affiliates). There were also no changes among its major affiliates.」
The filing explicitly states that there were no material changes in the business activities or principal affiliates. - FY2016First statedAnnual report
「The Group comprises 7 companies: the company submitting consolidated financial statements (hereinafter, the “Company”), 3 consolidated domestic subsidiaries, 1 unconsolidated domestic subsidiary and 2 unconsolidated overseas subsidiaries. Its principal business is the manufacture and sale of prescription pharmaceuticals, along with the purchase and sale of related materials, systems development and information processing, construction contracting, facility and equipment management, information gathering and development support, and other services.」
The Group operates a pharmaceutical business as its core business, as well as other businesses including information services, merchandise sales and construction contracting.